CRBU
Price
$2.04
Change
-$0.05 (-2.38%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
189.73M
7 days until earnings call
GYRE
Price
$6.90
Change
-$0.12 (-1.71%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
627.34M
14 days until earnings call
Interact to see
Advertisement

CRBU vs GYRE

Header iconCRBU vs GYRE Comparison
Open Charts CRBU vs GYREBanner chart's image
Caribou Biosciences
Price$2.04
Change-$0.05 (-2.38%)
Volume$46.28K
Capitalization189.73M
Gyre Therapeutics
Price$6.90
Change-$0.12 (-1.71%)
Volume$815
Capitalization627.34M
CRBU vs GYRE Comparison Chart in %
Loading...
CRBU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBU vs. GYRE commentary
Aug 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Buy and GYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 06, 2025
Stock price -- (CRBU: $2.04 vs. GYRE: $6.92)
Brand notoriety: CRBU and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBU: 64% vs. GYRE: 36%
Market capitalization -- CRBU: $189.73M vs. GYRE: $627.34M
CRBU [@Biotechnology] is valued at $189.73M. GYRE’s [@Biotechnology] market capitalization is $627.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $215.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBU’s FA Score shows that 0 FA rating(s) are green whileGYRE’s FA Score has 1 green FA rating(s).

  • CRBU’s FA Score: 0 green, 5 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRBU and GYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBU’s TA Score shows that 5 TA indicator(s) are bullish while GYRE’s TA Score has 3 bullish TA indicator(s).

  • CRBU’s TA Score: 5 bullish, 4 bearish.
  • GYRE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRBU is a better buy in the short-term than GYRE.

Price Growth

CRBU (@Biotechnology) experienced а +4.08% price change this week, while GYRE (@Biotechnology) price change was -5.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.41%. For the same industry, the average monthly price growth was +15.08%, and the average quarterly price growth was +12.00%.

Reported Earning Dates

CRBU is expected to report earnings on Nov 11, 2025.

GYRE is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (-0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($627M) has a higher market cap than CRBU($190M). CRBU YTD gains are higher at: 32.075 vs. GYRE (-41.983). GYRE has higher annual earnings (EBITDA): 12.1M vs. CRBU (-159.14M). CRBU has more cash in the bank: 208M vs. GYRE (29.9M). GYRE has less debt than CRBU: GYRE (1.59M) vs CRBU (26.2M). GYRE has higher revenues than CRBU: GYRE (101M) vs CRBU (9.92M).
CRBUGYRECRBU / GYRE
Capitalization190M627M30%
EBITDA-159.14M12.1M-1,315%
Gain YTD32.075-41.983-76%
P/E RatioN/A346.00-
Revenue9.92M101M10%
Total Cash208M29.9M696%
Total Debt26.2M1.59M1,653%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
93
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
9
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRBUGYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 14 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRBU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDTZX24.67N/A
N/A
Fidelity Advisor Capital Development M
EACPX60.50N/A
N/A
Eaton Vance Tax-Managed Multi-Cap Gr A
DURIX13.99N/A
N/A
DWS ESG International Core Eq Instl
MBIRX55.64N/A
N/A
Morgan Stanley Insight IR
BDAUX31.70N/A
N/A
Baron Durable Advantage R6

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+5.56%
BEAM - GYRE
40%
Loosely correlated
+1.54%
SPRC - GYRE
38%
Loosely correlated
+5.64%
AURA - GYRE
38%
Loosely correlated
-1.93%
RCKT - GYRE
36%
Loosely correlated
+2.68%
CRBU - GYRE
35%
Loosely correlated
+7.69%
More